Emergence Of New Myeloma Drugs, And Combinations, Raises Red Flag On Costs
Combinations of two or more branded drugs likely mean better potency and sales across the board, but mounting costs are likely to raise red flag with payers.
You may also be interested in...
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.